AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12426672 — intervention group
Group type: COMPARATOR
Intervention: No further radiotherapy (control)
Number of subjects: 207
Study 12426672 — intervention group
Group type: EXPERIMENTAL
Intervention: Boost (either electron or HDR BT)
Number of subjects: 207
Study 12426672 — intervention group
Group type: EXPERIMENTAL
Intervention: HDR BT
Number of subjects: 207
Study 12426672 — intervention group
Group type: EXPERIMENTAL
Intervention: Electron boost
Number of subjects: 207
Study 10487192 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (GBP), 2,400 mg/day
Number of subjects: 35
Study 10487192 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ), mean 731 mg/day
Number of subjects: 35
Study 10487192 — intervention group
Group type: COMPARATOR
Intervention: Nondrug average
Number of subjects: 35
Study 8754957 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthmatic patients at high altitude (2nd night)
Number of subjects: 8
Study 8754957 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls at high altitude (2nd night)
Number of subjects: 8
Study 8754957 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthmatic patients at high altitude (7th night)
Number of subjects: 8
Study 8754957 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls at high altitude (7th night)
Number of subjects: 8
Study 1912554 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human erythropoietin (rhEPO) at a dose of 1,200 to 1,600 U/kg intravenously (IV) twice weekly
Number of subjects: 20
Study 1912554 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 6125180 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol 0.4 mg i.v. (n = 10)
Number of subjects: 21
Study 6125180 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol 5 mg i.v. (n = 11)
Number of subjects: 21
Study 31313807 — intervention group
Group type: EXPERIMENTAL
Intervention: Written plus video instructions (video group)
Number of subjects: 120
Study 31313807 — intervention group
Group type: COMPARATOR
Intervention: Written preoperative instructions (control)
Number of subjects: 120
Study 30864618 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual chest compression (MCC) with PEEP-ZEEP maneuver
Number of subjects: 10
Study 30864618 — intervention group
Group type: COMPARATOR
Intervention: PEEP-ZEEP maneuver without MCC
Number of subjects: 10
Study 28724171 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-glucan, inositol and digestive enzymes (one tablet after lunch and dinner for four weeks)
Number of subjects: 43
Study 28724171 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (systemic and topical mesalamine)
Number of subjects: 43
Study 27180954 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl-L-carnitine (ALC) 500 mg t.i.d.
Number of subjects: 232
Study 27180954 — intervention group
Group type: COMPARATOR
Intervention: Methylcobalamin (MC) 0.5 mg t.i.d.
Number of subjects: 232
Study 27180954 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ALC and MC
Number of subjects: 232
Study 24618331 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D CEUS
Number of subjects: 23
Study 24618331 — intervention group
Group type: COMPARATOR
Intervention: 2D CEUS
Number of subjects: 23
Study 24618331 — intervention group
Group type: COMPARATOR
Intervention: CTA
Number of subjects: 23
Study 21278624 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 infected women
Number of subjects: 0
Study 21278624 — intervention group
Group type: EXPERIMENTAL
Intervention: HSV-2 infected women
Number of subjects: 0
Study 19720444 — intervention group
Group type: EXPERIMENTAL
Intervention: AEDs with open lid mechanism
Number of subjects: 120
Study 19720444 — intervention group
Group type: EXPERIMENTAL
Intervention: AEDs with pull handle mechanism
Number of subjects: 120
Study 19720444 — intervention group
Group type: COMPARATOR
Intervention: AEDs with push button mechanism
Number of subjects: 120
Study 19720444 — intervention group
Group type: EXPERIMENTAL
Intervention: AEDs with detailed voice instruction for pad placement
Number of subjects: 120
Study 19720444 — intervention group
Group type: COMPARATOR
Intervention: AEDs without detailed voice instruction for pad placement
Number of subjects: 120
Study 19720444 — intervention group
Group type: EXPERIMENTAL
Intervention: AEDs with step-by-step CPR instruction
Number of subjects: 120
Study 19720444 — intervention group
Group type: COMPARATOR
Intervention: AEDs that only prompted to start CPR
Number of subjects: 120
Study 19720444 — intervention group
Group type: EXPERIMENTAL
Intervention: All AED models
Number of subjects: 120
Study 17543680 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid Angioplasty with Stent placement (CAS)
Number of subjects: 24
Study 17543680 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid Endarterectomy (CEA)
Number of subjects: 24
Study 17543680 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 24
Study 15120657 — intervention group
Group type: EXPERIMENTAL
Intervention: Competency decomposition method for ontology specification
Number of subjects: 0
Study 15120657 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard method for developing domain ontologies
Number of subjects: 0
Study 15120657 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled trials (RCTs)
Number of subjects: 0
Study 11347658 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish (n = 13; 32 lesions)
Number of subjects: 31
Study 11347658 — intervention group
Group type: COMPARATOR
Intervention: Professional tooth-cleaning (n = 18; 30 lesions)
Number of subjects: 31
Study 9154674 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymostimulin (1 mg/kg day for the 1st week followed by once a week for 6 months)
Number of subjects: 78
Study 9154674 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment for COPD (Control group)
Number of subjects: 78
Study 9154674 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymostimulin
Number of subjects: 78
Study 7696830 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal HRT (continuous 17 beta‐oestradiol 0.05 mg/day, with 0.25 mg/day of norethisterone acetate for 14 days of each 28‐day cycle)
Number of subjects: 66
Study 7696830 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral HRT (continuous conjugated equine oestrogens 0.625 mg/day, with 0.15 mg/day dl‐norgestrel for 12 days of each 28‐day cycle)
Number of subjects: 66
Study 7696830 — intervention group
Group type: COMPARATOR
Intervention: Untreated group (30 matched untreated women)
Number of subjects: 66
Study 3301985 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral immunotherapy with enterosoluble capsules (cumulated dose of 280 times 10(6) biologic units of birch pollen extract)
Number of subjects: 39
Study 3301985 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral immunotherapy with enterosoluble capsules
Number of subjects: 39
Study 3301985 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 39
Study 28843974 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-violent video game (FIFA)
Number of subjects: 72
Study 28843974 — intervention group
Group type: EXPERIMENTAL
Intervention: Violent video game (Call of Duty)
Number of subjects: 72
Study 28843974 — intervention group
Group type: COMPARATOR
Intervention: Non-violent television (control group)
Number of subjects: 72
Study 26836910 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age group (≥ 65 years)
Number of subjects: 2627
Study 25492496 — intervention group
Group type: EXPERIMENTAL
Intervention: Injury Prevention Briefing (IPB) supplemented by initial training and regular facilitation
Number of subjects: 24
Study 25492496 — intervention group
Group type: COMPARATOR
Intervention: Injury Prevention Briefing (IPB) sent by post with no facilitation
Number of subjects: 24
Study 25492496 — intervention group
Group type: EXPERIMENTAL
Intervention: Injury Prevention Briefing (IPB)
Number of subjects: 24
Study 22770948 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Choices program (PC)
Number of subjects: 449
Study 22770948 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 449
Study 20493183 — intervention group
Group type: EXPERIMENTAL
Intervention: Mud bath treatments combined with hydropinotherapy (Group A)
Number of subjects: 0
Study 20493183 — intervention group
Group type: EXPERIMENTAL
Intervention: Mud bath treatments without hydropinotherapy (Group B)
Number of subjects: 0
Study 20493183 — intervention group
Group type: COMPARATOR
Intervention: No spa therapies (Group C)
Number of subjects: 0
Study 18076257 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex training
Number of subjects: 45
Study 18076257 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric-only training
Number of subjects: 45
Study 18076257 — intervention group
Group type: COMPARATOR
Intervention: Heavy resistance training
Number of subjects: 45
Study 16115985 — intervention group
Group type: EXPERIMENTAL
Intervention: Visible monitoring of cerebral oxygen saturation (rSO(2)) maintained at > or =75% of preinduction values (n = 56)
Number of subjects: 122
Study 16115985 — intervention group
Group type: COMPARATOR
Intervention: Blinded monitoring with routine anesthesia management (n = 66)
Number of subjects: 122
Study 16115985 — intervention group
Group type: EXPERIMENTAL
Intervention: Visible monitoring of rSO(2)
Number of subjects: 122
Study 16115985 — intervention group
Group type: COMPARATOR
Intervention: Blinded monitoring with routine anesthesia management
Number of subjects: 122
Study 16115985 — intervention group
Group type: COMPARATOR
Intervention: Control group with intraoperative cerebral desaturation
Number of subjects: 122
Study 12324722 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction pneumoplasty
Number of subjects: 60
Study 12324722 — intervention group
Group type: COMPARATOR
Intervention: Respiratory rehabilitation
Number of subjects: 60
Study 10425301 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-intensive chemotherapy (DI-PVM) consisting of 3 cycles of cisplatin: 80 mg/m2 (day 1), vindesine: 3 mg/m2 (days 1 and 8), and mitomycin C: 8 mg/m2 (day 1) in 3-week intervals with concurrent G-CSF.
Number of subjects: 100
Study 10425301 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy (PVM) consisting of 2 cycles of the same chemotherapy in 4-week intervals.
Number of subjects: 100
Study 7588144 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebound tenderness
Number of subjects: 123
Study 7588144 — intervention group
Group type: COMPARATOR
Intervention: Other physical signs (guarding, rigidity, Rovsing's sign)
Number of subjects: 123
Study 2138974 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestodene (GES)
Number of subjects: 0
Study 2138974 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel (LNG)
Number of subjects: 0
Study 2138974 — intervention group
Group type: COMPARATOR
Intervention: Both GES and LNG
Number of subjects: 0
Study 111275 — intervention group
Group type: EXPERIMENTAL
Intervention: Clorgyline (selective MAO‐A inhibitor)
Number of subjects: 0
Study 111275 — intervention group
Group type: EXPERIMENTAL
Intervention: Pargyline (selective MAO‐B inhibitor)
Number of subjects: 0
Study 111275 — intervention group
Group type: COMPARATOR
Intervention: Clorgyline and Pargyline
Number of subjects: 0
Study 30615024 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPABLE intervention (10 home visits over 5 months by occupational therapists, registered nurses, and home modifiers)
Number of subjects: 300
Study 30615024 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPABLE intervention
Number of subjects: 300
Study 30615024 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 social home visits by a research assistant)
Number of subjects: 300
Study 27863460 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Olympic education programme
Number of subjects: 841
Study 27863460 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Olympic education programme)
Number of subjects: 841
Study 26298619 — intervention group
Group type: EXPERIMENTAL
Intervention: 3F-PCC 25 IU/kg
Number of subjects: 24
Study 26298619 — intervention group
Group type: EXPERIMENTAL
Intervention: 3F-PCC 50 IU/kg
Number of subjects: 24
Study 26298619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 26298619 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg
Number of subjects: 24
Study 26298619 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 180 mg
Number of subjects: 24
Study 26298619 — intervention group
Group type: EXPERIMENTAL
Intervention: 3F-PCC infusion
Number of subjects: 24
Study 23365005 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular and systematic exercise regimens
Number of subjects: 40
Study 23365005 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 40
Study 22011892 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser irradiation (1.5 W, 100 mJ, 15 Hz)
Number of subjects: 34
Study 22011892 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional treatment, filled with vertically condensed gutta-percha)
Number of subjects: 34
Study 19228209 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate post‐space preparation with Resilon/Epiphany
Number of subjects: 80
Study 19228209 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed post‐space preparation (5 days later) with Resilon/Epiphany
Number of subjects: 80
Study 19228209 — intervention group
Group type: COMPARATOR
Intervention: Positive control (Resilon master cones without sealer)
Number of subjects: 80
Study 19228209 — intervention group
Group type: COMPARATOR
Intervention: Negative control (not obturated, sealed with fingernail polish)
Number of subjects: 80
Study 15978846 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg of sultopride
Number of subjects: 13
Study 15978846 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of fluvoxamine
Number of subjects: 13
Study 15978846 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 12553591 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous synthetic human secretin (2 IU/kg)
Number of subjects: 42
Study 12553591 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline placebo
Number of subjects: 42
Study 10609208 — intervention group
Group type: EXPERIMENTAL
Intervention: Healon GV (sodium hyaluronate 1.4%)
Number of subjects: 140
Study 10609208 — intervention group
Group type: COMPARATOR
Intervention: Viscoat (sodium chondroitin sulfate 4.0%‐sodium hyaluronate 3.0%)
Number of subjects: 140
Study 10609208 — intervention group
Group type: COMPARATOR
Intervention: Viscoat
Number of subjects: 140
Study 7503516 — intervention group
Group type: EXPERIMENTAL
Intervention: Syringe-assisted liposuction using the superwet or tumescent technique
Number of subjects: 22
Study 7503516 — intervention group
Group type: EXPERIMENTAL
Intervention: Syringe-assisted liposuction
Number of subjects: 22
Study 2248121 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention and cognitive intervention focused on changing maladaptive self-statements
Number of subjects: 63
Study 2248121 — intervention group
Group type: COMPARATOR
Intervention: Behavioral intervention
Number of subjects: 63
Study 2248121 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention and cognitive intervention
Number of subjects: 63
Study 7027279 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone (TZ)
Number of subjects: 43
Study 7027279 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline (AMT)
Number of subjects: 43
Study 31703648 — intervention group
Group type: EXPERIMENTAL
Intervention: Per‐oral carbohydrate load (preOp™) 18 and 2‐4 h before surgery (n=26)
Number of subjects: 61
Study 31703648 — intervention group
Group type: COMPARATOR
Intervention: Standard pre‐operative fasting with free consumption of tap water (n=35)
Number of subjects: 61
Study 31703648 — intervention group
Group type: EXPERIMENTAL
Intervention: Per‐oral carbohydrate load (preOp™)
Number of subjects: 61
Study 28322474 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab (80 mg subcutaneous every 2 or 4 weeks after a 160 mg starting dose)
Number of subjects: 3866
Study 28322474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3866
Study 28322474 — intervention group
Group type: COMPARATOR
Intervention: Etanercept (50 mg biweekly)
Number of subjects: 3866
Study 25377269 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin administration (3 μg/kg, twice a day)
Number of subjects: 20
Study 25377269 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin administration (0.5 μg/kg/h continuous infusion)
Number of subjects: 20
Study 25377269 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin administration (both regimens)
Number of subjects: 20
Study 25377269 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ghrelin administration)
Number of subjects: 20
Study 24088225 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (200 mg for 4 days)
Number of subjects: 11
Study 24088225 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 11
Study 21107813 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-blocker monotherapy
Number of subjects: 60
Study 21107813 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal magnetic innervations (ExMI) monotherapy
Number of subjects: 60
Study 21107813 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (alpha-blocker + ExMI)
Number of subjects: 60
Study 19594851 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal ketorolac (31.5 mg) three times daily for up to 5 days
Number of subjects: 300
Study 19594851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 19594851 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal ketorolac
Number of subjects: 300
Study 17379850 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined EBUS and ENB
Number of subjects: 120
Study 17379850 — intervention group
Group type: COMPARATOR
Intervention: EBUS only
Number of subjects: 120
Study 17379850 — intervention group
Group type: COMPARATOR
Intervention: ENB only
Number of subjects: 120
Study 16283538 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion rates of the drug (individualized to achieve the same target concentration)
Number of subjects: 12
Study 16283538 — intervention group
Group type: EXPERIMENTAL
Intervention: Markov model for side-effect analysis
Number of subjects: 12
Study 16283538 — intervention group
Group type: COMPARATOR
Intervention: Model without Markov elements
Number of subjects: 12
Study 12076871 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily high dose interferon (IFN) for 6 weeks followed by standard therapy of 3 million units three times a week in combination with ribavirin for 42 weeks
Number of subjects: 28
Study 12076871 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice daily high dose interferon (IFN) for 6 weeks followed by standard therapy of 3 million units three times a week in combination with ribavirin for 42 weeks
Number of subjects: 28
Study 12076871 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction IFN therapy followed by combination IFN plus ribavirin
Number of subjects: 28
Study 10078675 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 1.0 mg intravenously and 2.0 mg intravenously
Number of subjects: 90
Study 10078675 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam emulsion 2.0 mg intravenously and 5.0 mg intravenously
Number of subjects: 90
Study 10078675 — intervention group
Group type: COMPARATOR
Intervention: Saline 2.0 ml intravenously
Number of subjects: 90
Study 7677415 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular vaccines
Number of subjects: 51
Study 7677415 — intervention group
Group type: COMPARATOR
Intervention: Whole cell vaccine
Number of subjects: 51
Study 2187453 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine A (Cy-A)
Number of subjects: 32
Study 2187453 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 7216144 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg FK 33‐824 i.m. after saline i.v.
Number of subjects: 12
Study 7216144 — intervention group
Group type: COMPARATOR
Intervention: 4 mg naloxone i.v. followed by 1 mg FK 33‐824 i.m.
Number of subjects: 12
Study 7216144 — intervention group
Group type: COMPARATOR
Intervention: 10 mg naloxone i.v. followed by 1 mg FK 33‐824 i.m.
Number of subjects: 12
Study 7216144 — intervention group
Group type: COMPARATOR
Intervention: saline i.v. followed by saline i.m.
Number of subjects: 12
Study 31924197 — intervention group
Group type: EXPERIMENTAL
Intervention: BUD/FORM
Number of subjects: 3576
Study 31924197 — intervention group
Group type: COMPARATOR
Intervention: FORM
Number of subjects: 3576
Study 31102918 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic risk information intervention
Number of subjects: 119
Study 31102918 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 119
Study 27567057 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-Articular Tranexamic Acid (IA TXA)
Number of subjects: 168
Study 27567057 — intervention group
Group type: COMPARATOR
Intervention: Intravenous Tranexamic Acid (IV TXA)
Number of subjects: 168
Study 26015327 — intervention group
Group type: EXPERIMENTAL
Intervention: SOLE
Number of subjects: 18
Study 26015327 — intervention group
Group type: EXPERIMENTAL
Intervention: SuperFeet
Number of subjects: 18
Study 26015327 — intervention group
Group type: EXPERIMENTAL
Intervention: Powerstep
Number of subjects: 18
Study 26015327 — intervention group
Group type: COMPARATOR
Intervention: No orthotic
Number of subjects: 18
Study 25109299 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented Communication‐Output (AC‐O) intervention using speech‐generating devices (SGD)
Number of subjects: 0
Study 25109299 — intervention group
Group type: COMPARATOR
Intervention: Augmented Communication‐Input (AC‐I) intervention using speech‐generating devices (SGD)
Number of subjects: 0
Study 22323636 — intervention group
Group type: COMPARATOR
Intervention: Responses in V1, LOC, and hMT+ ROIs with gaps >0.5°
Number of subjects: 0
Study 22323636 — intervention group
Group type: COMPARATOR
Intervention: Responses in V4 and V3A ROIs with gaps up to 5.5°
Number of subjects: 0
Study 22323636 — intervention group
Group type: EXPERIMENTAL
Intervention: V3A ROI sensitivity to disparity noise
Number of subjects: 0
Study 20196388 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral steroids for Class II patients
Number of subjects: 18
Study 20196388 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide 2 mg/kg/d for 12 weeks for Class III patients
Number of subjects: 18